Advances from genome sequencing are paving the way to personalized treatment for…

Blood cancers (leukemias) are life-threatening diseases that can devastate the lives of patients and their families. Great progress has been made in treatments to improve the survival of these otherwise invariably fatal conditions. Major advances in the understanding of leukemia genetics for genome sequencing of individual patients has taken us one step further towards realizing personalized medicine for many patients.

Read more

Leading Medical Organizations Join Forces Globally to Launch First-Ever World Th…


Leading Medical Organizations Join Forces Globally
to Launch First-Ever World Thrombosis Day

The International Society on Thrombosis and Haemostasis (ISTH) partners with thrombosis related organizations from every continent to launch World Thrombosis Day focused on single cause of top 3 cardiovascular deaths worldwide.

EHA endorses and supports the initiative for this World Thromobis Day.

Read more

Treatment, medicine and hematology research: What patients want and doctors need…

The European Hematology Association is organizing its 19th Congress in Milan, Italy- June 12-15, 2014.

Following last year’s successful introduction, the EHA congress program will be complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.


Read more

European Hematologists will discuss breakthroughs in blood disorders in Milan, I…

The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 19th Congress of EHA.More than 9,500 participants from around the world are expected at the upcoming 19th Congress of the European Hematology Association at the MiCo - Milano Congressi in Milan, Italy from June 12-15, 2014.


Read more

Sanquin Blood Supply will culture erythrocytes for transfusion purposes

Transfusion of erythrocytes is the most common form of cellular therapy. It rapidly restores the oxygen supply to the tissues in patients suffering from sudden blood loss, reduced erythrocyte production following for instance cytotoxic cancer treatment, or in patients suffering from chronic anemia due to congenital diseases such as sickle cell disease and thalassemia. Matching transfusions for ABO and Rh-D blood group antigens is in general sufficient for successful transfusion. However, over 300 additional blood group antigens are known, against which we do not normally generate antibodies, and that are not matched for in general transfusion practice.

Read more

Press release: 18th Congress of the European Hematology Association in Stockholm…

Since 2010 the European Hematology Association (EHA) and the Wallace H Coulter Foundation (WHCF) have been in a close partnership, in which EHA was the beneficiary of generous donations for its projects. The support of the WHCF has been the prime mover for the setup of the EHA-ASH Translational Research Training in Hematology (TRTH) program and an important contributor towards the vast expansion of EHA’s outreach program. Both programs have had a major impact on the Association’s array of activities and global network.

The importance of the achievements of Wallace Coulter, the inventor of the Coulter Counter - the most valuable tool in the hematology laboratory, as a person and his organization cannot be underestimated for the hematological community as well as for EHA due to the Foundation’s support. EHA is glad to be able to pay tribute and commemorate the 100th birthday of Wallace Coulter.

Read more

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be …

This year the Scientific Working Group Session on hematopoietic stem cells will focus on the recent advance in the field of “Induced Pluripotent Stem Cells (IPSC)”.

Read more

Press Release: News on Red Cells and Iron presented at the 18th Congress of the …

Iron deficiency anaemia continues to me the most common disease in the world, affecting millions of people, mostly women. Failure to find an underlying cause of iron deficiency and failure to respond to iron replacement often points to a completely different mechanism of anaemia which is usually congenital and surprisingly can lead to excess accumulation of iron and ill health.

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reporte…

Breaking news on Lymphoma (lymph node cancer) and Myeloma (plasma cell cancer) reported at meetings of Scientific Working Groups during the European Hematology Congress in Stockholm, June 13-16, 2013  

Read more

Press release: Theme of the Year and Patient Advocacy - 18th Congress of EHA - E…

The introduction of a European Hematology Association-Theme of the Year in June 2012, focusing on Quality of Life (QoL) in Hematology, was successful in stimulating awareness, conference sessions, publications, and reports.

The conclusion, in June 2013, of this year’s theme includes two editorials in Haematologica entitled “Patients’ needs in hematology: whose perspectives?” and “Age and Aging in blood disorders: EHA Theme of the Year 2013-2014’’. The Scientific Working Group Quality of Life and Symptoms will organize a SWG Session “Implementation of treatment related patient-reported outcomes in routine clinical practice in hematological malignancies”. Although each theme of the year is introduced to highlight a certain topic in hematology, the themes will remain active. Therefore, Quality of Life will stay on the agenda.

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of th…

Hematopoietic stem cells (HSCs) regenerate blood cells throughout the lifespan of an individual.  The HSC pool has to accommodate to the cellular stresses associated with its life-long activity. HSCs are protected in specific bone marrow areas called “niches”. New technologies allow the analysis of different bone marrow compartments and the functional implications on HSCs.  HSCs persist for a lifetime; there is a balance between their proliferation and their quiescent (sleeping) state. Therefore, the HSCs cell cycle is controlled by factors within and outside the cell.

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be…

The word ‘leukemia’ fills people with awe and foreboding. Things have changed, however, for the better. In children who have Acute Lymphoblastic Leukemia (ALL) the cure rate is about 90%. In adults the story is not so good. The predominant type of leukemia in adults is Acute Myeloid Leukemia (AML) and most patients are over 60 years of age. Although age was felt to be an important factor in the poor responses seen in adults, it is now clear that Acute Leukemia in older patients is a different disease which is intrinsically resistant to traditional chemotherapy.


Read more

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell ca…

To date, up to 80% of patients with the most common subtype of malignant lymphoma (diffuse large B-cell lymphoma), are cured of this aggressive disease by chemotherapy, in combination with the anti-lymphoma antibody Rituximab. Unfortunately, young patients with high risk disease and elderly patients fare much worse and there is an urgent need to improve their outcome. However, the past year has seen a significant increase in our knowledge of the biology of disease. Using gene expression profiling and other new molecular techniques, we are beginning to recognize/identify the disease driver pathways which make lymphoma cells continue to proliferate. These major advances will be extensively reported at the meeting.  The first results of clinical studies with new "smart molecules", such as lenalidomide, enzastaurin, bortezomib and ibrutinib, to mention a few, that specifically kill the cancer cells with only minimal damage to normal tissues/organs will be presented. So far, this modern "personalized medicine" approach appears to be promising, in particular for patients who only respond poorly to conventional treatment.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukem…

At the 54th Annual Meeting of ASH, Dr Francesco Lo Coco, lead author and Chairman of the APL subcommittee of the Italian GIMEMA group and Professor of Hematology at University Tor Vergata in Rome, Italy, presented the outcome of new research that demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute leukemia.

Read more

PRESS RELEASE: Cyprus Presidency promotes win-win on health and competitiveness

Brussels, 20 Nov: Economic growth and lower healthcare costs are both possible if Europe exploits the opportunities of personalised healthcare, according to a report prepared under the aegis of the Cyprus Presidency of the EU.

Read more